Neuroendocrine tumours: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PD-1 1
• BRAF 0
• TP53 1
• PD-L1 0
• DLL3 14
• PI3K 0
• CTLA-4 0
• mTOR 1
• STAT3 0
• AKT 0
• MEK 0
• MAPK 0
• VEGF 1
• RET 0
• ERK 0
• STING 0
• YAP 0
• PRAME 0
• CTNNB1 0
• NRAS 0
• BAP1 0
• PTEN 0
• ALK 0
• EGFR 1
• MYC 0
• CXCR4 0
• EZH2 0
• HIF-1 0
• HSP90 0
• JNK 0
• PARP 5
• PSMA 3
• TNF 0
• CD40 0
• CDK4/6 0
• GPX4 0
• NRF2 0
• VHL 3
• AMPK 0
• B7-H3 2
• COX-2 0
• KRAS 0
• PPAR 0
• CD47 1
• KIT 1
• RAS 0
• TERT 0
• BRCA2 0
• CDKN2A 0
• GLP-1 0
• HER2 1
• IGF1R 0
• IL-17 0
• LAG-3 0
• MET 0
• MMP-9 0
• RB1 1
• TIGIT 0
• TROP2 1
• AXL 0

EU-13 is a filter, not a ranking: it only narrows the list.

2 of 2+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

  NCT04538378· National Cancer Institute (NCI)· Updated 22 Sept 2026

  “Closed due to slow accrual.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

  NCT04086485· National Cancer Institute (NCI)· Source

• Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

  NCT04538378· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 50
• Organoids 14
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 13
• Gene Expression Profiling 118
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 10
• Exome Sequencing 13
• Proteomics 49
• Metabolomics 20
• Mass Spectrometry 4
• Flow Cytometry 55
• Immunohistochemistry 185
• Liquid Biopsy 9
• Circulating Tumor DNA 35
• Xenograft Model Antitumor Assays 117
• Positron-Emission Tomography 61
• Magnetic Resonance Imaging 200
• Machine Learning 53
• Deep Learning 53
• Cohort Studies 80
• Genome-Wide Association Study 12

• [Comparison of clinical characteristics and MRI functional parameters between choroidal melanoma and choroidal hemangioma].

  Zhonghua Yan Ke Za Zhi, Nov 2026

• Multiple Machine Learning Algorithms for Predicting Postoperative Residual Tumor in Pituitary Neuroendocrine Tumors.

  CNS Neurosci Ther, Nov 2026

• Altered Neural Pitch Encoding in Vestibular Schwannoma: Evidence From Frequency-Following Responses.

  J Otolaryngol Head Neck Surg, Oct 2026

• MRI-Based Radiomics Model for Pretreatment Prediction of Pathological Lymph Node Metastasis in Neuroendocrine Carcinoma of the Cervix: Dual-Center Development and External Validation.

  Curr Oncol, Oct 2026

• Imaging Manifestations and Clinical Analysis of 12 Cases of Anorectal Malignant Melanoma.

  Ann Ital Chir, Oct 2026

• Atypical presacral masses in Currarino syndrome: a case series.

  Childs Nerv Syst, Oct 2026

• Management of Brachial Plexus Neurogenic Tumors: A Retrospective Study of 25 Cases.

  J Surg Res, Oct 2026

• Non-invasive Imaging Modalities for Breslow Thickness Estimation in Melanoma: A Scoping Review.

  Skin Res Technol, Oct 2026

• Ventral Cervical Spinal Schwannoma Presenting as Progressive Myelopathy.

  Ir Med J, Sept 2026

• Case Report: Pituitary apoplexy temporally associated with acute alcohol intoxication, presenting as complete oculomotor nerve palsy in an SF-1 lineage gonadotroph PitNET.

  Front Endocrinol (Lausanne), Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.